A new @AJMC_Journal article highlights BriaCell’s Bria-IMT™ as an off-the-shelf #immunotherapy being evaluated for patients with #metastaticbreastcancer following treatment with antibody-drug conjugates (ADCs). The article highlights the ongoing pivotal Phase 3 Bria-ABC study, final Phase 2 data showing a median overall survival of 16.6 months, and recent biomarker findings presented at #ESMO26. Read the full article: bit.ly/3CgzknU $BCTX $BCTXL

BriaCell’s Chief Medical Officer, Dr. Giuseppe Del Priore, highlights findings presented at the #ESMO26 Congress supporting further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit in #metastaticbreastcancer. Learn more: bit.ly/4yGWuOd $BCTX $BCTXL

BriaCell will present new clinical biomarker findings at the #ESMO26 Congress highlighting CAML PD-L1 as a potential biomarker of clinical outcomes in #metastaticbreastcancer. “We are encouraged by these findings showing that dynamic changes in a circulating immune biomarker were associated with progression-free and overall survival in patients with metastatic breast cancer treated with immunotherapies,” stated Dr. William V. Williams, BriaCell’s President and CEO. For more: bit.ly/4yGWuOd $BCTX $BCTXL

BriaCell announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with #metastaticbreastcancer treated with immune based therapies including the BriaCell regimen at the #ESMO26 Congress, taking place October 23-27, 2026 in Madrid, Spain. The data shown is pooled from several studies including BriaCell’s Phase 1/2 Bria-IMT study. For additional presentation information: bit.ly/4yGWuOd $BCTX $BCTXL

BriaCell CEO Dr. William V. Williams recently joined The Bio Report, hosted by Daniel Levine, to discuss the development of BriaCell’s off-the-shelf, cell-based #immunotherapies for #metastaticbreastcancer. Listen to the full interview: bit.ly/3CgzknU $BCTX $BCTXL #TheBioReport

BriaCell is featured in a recent @PrismMarketView article, “Closing the Gap: Emerging Biotechs Take Aim at Metastatic Breast Cancer.” The article highlights the continued unmet need in #metastaticbreastcancer and BriaCell’s pivotal Phase 3 Bria-ABC study evaluating Bria-IMT in combination with a checkpoint inhibitor. Read the full article: bit.ly/3CgzknU $BCTX $BCTXL

Join us in recognizing Men's #BreastCancerAwareness Week, October 17-23. While #breastcancer is more common in women, it can also affect men. This week, we're highlighting the importance of awareness, education and research for everyone impacted by #breastcancer. Learn more: bit.ly/3EwJcKQ #BCAM #noveltherapies #cancertherapies #MBC

BriaCell CEO Dr. William V. Williams joins Johny Fernandez of @fintechtvglobal to discuss the company’s pivotal Phase 3 trial of Bria-IMT and the progress toward its headline data readout. Dr. Williams also highlights Bria-OTS, BriaCell’s off-the-shelf immunotherapy approach designed to match more than 99% of patients, and encouraging clinical results observed in metastatic breast cancer. Watch the full interview: bit.ly/3CgzknU $BCTX $BCTXL

On #NationalMammographyDay, we're highlighting the importance of #BreastCancer screening and early detection. Regular screening can help detect breast cancer earlier, when it may be easier to treat. BriaCell is committed to advancing innovative approaches for people living with breast cancer. Learn more: bit.ly/3DgtmSu #breastcancerawareness #BCAM #noveltherapies #cancertherapies #MBC

BriaCell President and CEO Dr. William V. Williams was featured as a key speaker at The Scientist’s Virtual Symposium, “The Translational Potential of Cell and Gene Therapies.” The symposium brings together researchers and industry experts to discuss the development, optimization and translation of cell and gene therapies toward clinical applications across a range of disease areas. Watch the full presentation: bit.ly/3CgzknU $BCTX $BCTXL

October 13 is nationally recognized as #MetastaticBreastCancerAwarenessDay, helping raise awareness of #metastaticbreastcancer and the need for continued research toward new treatment options. Learn more about metastatic breast cancer and how you can get involved: bit.ly/3EwJcKQ #breastcancerawareness #BCAM #noveltherapies #cancertherapies #MBC

BriaCell has been shortlisted for the 2026 @Citeline Biotech Awards in the category of Excellence in Oncology! The award recognizes biotech companies advancing cancer treatment through scientific innovation and a commitment to addressing the needs of patients with limited treatment options. Winners will be announced at the awards ceremony on November 12, 2026, in Boston, MA. Learn more: bit.ly/3GBbcB1 $BCTX $BCTXL

This #BreastCancerAwarenessMonth, we’re highlighting the continued advancement of novel approaches for patients facing #metastaticbreastcancer. Bria-IMT™ is BriaCell’s off-the-shelf, cell-based immunotherapy being evaluated in a pivotal Phase 3 clinical trial in combination with an immune checkpoint inhibitor. Learn more: bit.ly/3q4udjN #breastcancerawareness #BCAM #noveltherapies #cancertherapies #MBC

BriaCell and its majority-owned subsidiary, BriaPro, announced that four abstracts featuring preclinical research from their respective #immunotherapy programs have been selected for poster presentations at the @sitcancer 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ. The presentations will feature BriaCell’s personalized off-the-shelf #immunotherapy, Bria-OTS+™ and BriaPro’s research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants. Presentation details can be found here: bit.ly/4hvkTRN #SITC26 $BCTX $BCTXL

BriaCell CEO Dr. William V. Williams was featured in @IBDinvestors discussing the renewed momentum surrounding therapeutic cancer vaccines following recent Phase 3 results from #Moderna and #Merck. Dr. Williams shared his perspective on the potential of the approach and the broader role of mRNA technology in #oncology. “I think the cancer space is definitely where the mRNA technology can shine,” said Dr. Williams. Read the full article, here: bit.ly/3CgzknU $BCTX $BCTXL

October marks #BreastCancerAwarenessMonth. According to the American Cancer Society, breast cancer deaths in 2026 are estimated to be 42,670 (42,140 women, 530 men), making breast cancer the second leading cause of cancer death in women. Learn more about breast cancer and the importance of awareness, research and continued innovation: bit.ly/3EwJcKQ #BCAM #noveltherapies #MBC

A new @sambasci feature explores BriaCell’s innovative approach to cancer #immunotherapy, including Bria-IMT™, HLA matching and the potential for more accessible cell therapy. Read the full feature: bit.ly/3CgzknU $BCTX $BCTXL #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #sambascientific

BriaCell is featured in @CUREtoday’s roundup, “7 Breast Cancer Clinical Trials Currently Enrolling in the US,” highlighting the Company’s Bria-ABC Phase 3 clinical trial of Bria-IMT™ for advanced #metastaticbreastcancer. Read the full article: bit.ly/3CgzknU $BCTX $BCTXL

From podcasts and Q&As to articles and contributed bylines, BriaCell CEO Dr. William Williams has recently shared his perspective on BriaCell’s progress and novel approach to cancer immunotherapy. We invite you to read and listen to these recent interviews and features to learn more about BriaCell, our approach, and the evolving cancer treatment landscape: briacell.com/media-coverage/ $BCTX $BCTXL

Dr. William V. Williams, President & CEO of BriaCell, joins the Biotech Insiders podcast to discuss the Company’s latest developments, vision for the future and opportunities ahead. Listen to the full episode: bit.ly/3VrB3Tv $BCTX $BCTXL